Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability and Effects on Arterial Structure and Function of ACZ885 in Patients With Intermittent Claudication.
Conditions
Interventions
Canakinumab (ACZ885)
Placebo
Locations
14
United States
Novartis Investigative Site
Phoenix, Arizona, United States
Novartis Investigative Site
Jacksonville, Florida, United States
Novartis Investigative Site
Jacksonville, Florida, United States
Novartis Investigative Site
Chicago, Illinois, United States
Novartis Investigative Site
Lutherville, Maryland, United States
Novartis Investigative Site
Columbus, Ohio, United States
Start Date
October 30, 2012
Primary Completion Date
August 4, 2016
Completion Date
August 4, 2016
Last Updated
April 29, 2025
NCT06212271
NCT07283289
NCT06003855
NCT05628948
NCT04794530
NCT06033924
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions